1. Home
  2. NAAS vs SCLX Comparison

NAAS vs SCLX Comparison

Compare NAAS & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NaaS Technology Inc.

NAAS

NaaS Technology Inc.

HOLD

Current Price

$3.35

Market Cap

41.7M

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$5.35

Market Cap

35.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAAS
SCLX
Founded
2019
2011
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.7M
35.2M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
NAAS
SCLX
Price
$3.35
$5.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
16.2K
30.7K
Earning Date
05-12-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$30,253,000.00
Revenue This Year
N/A
$122.52
Revenue Next Year
N/A
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.80
$4.20
52 Week High
$4.36
$30.90

Technical Indicators

Market Signals
Indicator
NAAS
SCLX
Relative Strength Index (RSI) 52.68 44.37
Support Level $3.20 $4.85
Resistance Level $3.52 $7.77
Average True Range (ATR) 0.17 0.28
MACD 0.01 0.08
Stochastic Oscillator 60.78 57.47

Price Performance

Historical Comparison
NAAS
SCLX

About NAAS NaaS Technology Inc.

Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: